Nanjing Geneseeq Technology
Nanjing Geneseeq Technology is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A global, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3)
Sponsor Ascentage Pharma Group Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Sponsor Zai Lab (US) LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nanjing Geneseeq Technology?
The 2026-10-09 snapshot links Nanjing Geneseeq Technology to 2 distinct CTIS trials. Recorded services include Biomarker testing, Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nanjing Geneseeq Technology?
The most frequently recorded therapeutic areas are Haematological Malignancies, Respiratory, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nanjing Geneseeq Technology conducted?
The linked trials record locations in 11 countries, including Spain, Italy, Poland, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Nanjing Geneseeq Technology delivered services.
What can this page tell me about Nanjing Geneseeq Technology's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nanjing Geneseeq Technology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nanjing Geneseeq Technology Inc.